Ferritin is a widely used marker of iron status. A relationship between iron stores, obesity and metabolic syndrome (METs) has been proposed. Objective: To compare serum ferritin between obese women with and without METs, and to evaluate the main factors accounting for ferritin levels. Design: Prospective study. Subjects: A total of 239 consecutive postmenopausal women with body mass index (BMI) X30 kg/m 2 were included. Exclusion criteria were conditions that could influence body iron stores. In addition to ferritin, serum iron, transferrin, transferrin saturation index and the soluble transferrin receptor were measured. METs was defined according to the International Diabetes Federation guidelines. Multiple regression analyses were performed taking into account ferritin as the dependent variable. Results: Serum ferritin levels were significantly higher in obese women with METs (n ¼ 169) in comparison with obese women without METs (n ¼ 70): 81.00 (17-648) vs 48.50 (11-149) ng ml À1 , Po0.001. No differences in the other markers of iron status were observed. Diabetic patients (n ¼ 82) had higher ferritin levels than non-diabetic patients (Po0.001). Non-diabetic patients with METs (n ¼ 95) also showed higher ferritin levels than non-diabetic patients without METs (P ¼ 0.001). Among the components of METs only diabetes was independently associated with serum ferritin levels in both the whole group (P ¼ 0.02) and in patients with METs (P ¼ 0.005). Conclusion: Metabolic syndrome and in particular type 2 diabetes is the main contributor to the high ferritin levels reported in obesity. Our findings suggest that ferritin should not be used as a reliable index of iron overload in obese patients with diabetes.
Introduction
Several studies have shown a relationship between obesity and serum levels of ferritin. Oshang et al. 1 reported that body mass index (BMI) and waist-to-thigh ratio were the strongest predictors of serum ferritin. In addition, two analyses from the Third National Health and Nutrition Examination Survey (NHANES) showed that serum ferritin was associated with abdominal obesity and other indices of body fat distribution. 2, 3 Recently, Illouz et al. 4 observed that the waist-to-hip circumference ratio was related to serum ferritin levels in obese type 2 diabetic patients with metabolic syndrome (METs). However, the results are difficult to interpret because other causes of iron overload such as alcohol consumption, or hemochromatosis gene mutations were not excluded. In addition, it should be noted that serum ferritin is an acute phase reactant 5 and, therefore, all inflammatory processes can eventually increase serum ferritin levels. Given that a low-grade inflammatory status is present in type 2 diabetic patients, 6, 7 this pathway has been involved in the high levels of ferritin reported in the diabetic population. 8 Furthermore, not only type 2 diabetes but also insulin resistance and METs have been associated with high ferritin levels. 2, 4 As high rates of METs and/or diabetes have been reported in obese patients, it could be hypothesized that the elevated levels of ferritin reported in obese patients is because of these associated conditions rather than obesity itself. To shed light on this issue, we have compared serum ferritin levels and other classical indices of iron stores between obese women with and without METs. In addition, the main contributor among the components of METs to serum ferritin levels has also been evaluated.
Methods
Patients A total of 239 consecutive women with BMI X30 kg/m 2 attending the outpatient Obesity Unit of a university hospital were prospectively recruited for the study from January to July 2007.
The exclusion criteria for this study were conditions that could influence body iron stores: premenopause, clinical evidence of hemorrhage in the preceding 6 months or serum ferritin levels o10 ng ml
À1
, iron treatment in the previous year, blood donation within the previous 6 months, alcohol consumption 450 g day , hemochromatosis (by testing hemochromatosis gene mutations C282Y and H63D in patients with transferring saturation index 445%), concomitant infections, and chronic diseases other than type 2 diabetes mellitus. Patients with type 1 diabetes were also excluded.
Metabolic syndrome was defined according to the new International Diabetes Federation (IDF) guidelines:
9 central obesity (waist circumference 494 cm for men and 480 cm for women), plus two of the following factors: (1) serum triglycerides X150 mg per 100 ml or specific treatment for this lipid abnormality; (2) high-density lipoprotein (HDL) cholesterol p40 mg per 100 ml in males and p50 mg per 100 ml in females or specific treatment for this lipid abnormality; (3) 
Statistical analysis
Normal distribution of the variables was evaluated using the Kolmogorov-Smirnov test. Given their skewed distribution, serum ferritin, sTfR, triglycerides, HOMA-IR and triglycerides-to-HDL ratio were expressed as median (range). Comparisons between groups were performed using analysis of variance and Student's t-tests for continuous variables and the w 2 test for categorical variables. The relationships between the continuous variables were examined by the Pearson's linear correlation test. To assess the variables independently related to serum ferritin in all the individuals included in the study, as well as in the patients with METs, stepwise multiple regression analyses were performed. Ferritin (log) was considered as the dependent variable, and the independent variables included in the analyses were age, BMI, triglycerides (log), HDL cholesterol, hypertension (yes/ no), type 2 diabetes (yes/no) and HOMA-IR (log). All P-values are based on a two-sided test of statistical significance. Significance was accepted at the level of Po0.05. Statistical analyses were performed with the SSPS statistical package (SAS Institute, Cary, NC, USA).
Results
The main clinical features and the laboratory data of the study population are presented in Table 1 . Serum ferritin levels were significantly higher in obese patients with METs than in obese patients without METs (Po0.001). However, no differences in serum iron, transferrin, transferrin saturation index and sTfR were observed. In univariate analysis, serum ferritin was positively correlated with age (r ¼ 0.263, Po0.001), plasma glucose (r ¼ 0.187, P ¼ 0.004), triglycerides (log) (r ¼ 0.154, P ¼ 0.017), and indices of insulin resistance: HOMA-IR (log) (r ¼ 0.236, P ¼ 0.004) and triglycerides-to-HDL ratio (log) (r ¼ 0.200, P ¼ 0.002). Diabetic patients (n ¼ 82) had higher ferritin levels than non-diabetic patients (n ¼ 157) (94.00 (17.00-648.00) vs 58.00 (11.00-219.00) respectively, Po0.001). Serum ferritin levels increased with the severity of glucose abnormalities (Table 2) . Non-diabetic patients with METs (n ¼ 95) also showed higher ferritin levels than non-diabetic patients without METs (n ¼ 62) (65.00 (19.00-219.00) vs 48.00 (11.00-179.00), P ¼ 0.001).
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Among patients with METs, those patients with diabetes had higher ferritin values than patients without diabetes (P ¼ 0.013) but no differences in serum iron, transferrin, transferrin saturation and index sTfR were observed (Table 3) . Apart from diabetes, serum ferritin levels were not significantly influenced by the presence of other components of METs: hypertension (82.00 (17.00-648.00) vs 63.00 (25.00-274.00), respectively, P ¼ 0.540), triglycerides (83.00 (19.00-286.00) vs 74.00 (17.00-648.00), respectively, P ¼ 0.615) and HDL cholesterol (82.00 (19.00-648.00) vs 78.00 (17.00-240.00), respectively, P ¼ 0.440). Sixty three (76.82%) of the 82 type 2 diabetic patients were under treatment with metformine: alone (n ¼ 34), associated with insulin (n ¼ 19) and combined with sulfonylureas (n ¼ 10). The remaining type 2 diabetic patients were only treated with lifestyle modification and diet (n ¼ 19). No differences in serum ferritin levels were observed among groups regarding the antidiabetic treatment received (P ¼ 0.286). In addition, no correlation was found between HbA1c and serum ferritin levels.
Multiple regression analyses showed that age and type 2 diabetes were independently associated with serum ferritin concentrations in both the whole group and when the analysis was restricted to obese patients with METs (Table 4) .
Discussion
In this study we provide evidence that obese patients with METs have significantly higher ferritin levels than obese patients without METs, diabetes being the main factor accounting for this finding.
Serum ferritin is a widely used marker of iron status in epidemiological studies and accurately reflects body iron stores in healthy individuals. 12 Several lines of evidence support the link between body iron excess and insulin resistance. 13, 14 In this regard, two prospective studies conducted in apparently healthy populations have shown that ferritin concentrations independently predict the development of type 2 diabetes. 15, 16 In fact, type 2 diabetes is a condition frequently associated with elevated levels of serum ferritin. 17, 18 However, it has been demonstrated that iron stores in liver autopsy specimens from type 2 diabetic patients were found to be not greater than in non-diabetic patients. 19 In addition, Bugianesi et al. 20 did not find a relationship between serum ferritin levels and hepatic iron content in patients with non-alcoholic fatty liver disease. Furthermore, we have reported that serum ferritin levels are increased in type 2 diabetic patients in the absence of a reciprocal decrease of sTfR, 8 thus suggesting that elevated ferritin levels in type 2 diabetes are mainly a result of an inflammatory mechanism rather than iron overload. Restricted to patients without current treatment with sulfonylureas or insulin (n ¼ 142 and n ¼ 68, respectively). IFG vs Type 2 diabetes, P ¼ 0.040. Type 2 diabetic patients also had higher serum ferritin levels than non-diabetic patients as a whole (o100 mg per 100 ml plus IFG): 94.00 (17.00-648.00) vs 58.00 (11.00-219.00), Po0.001).
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Serum sTfR concentration is closely related to cellular iron demands and, in consequence, the higher the ferritin levels the lower the sTfR concentration. In addition, sTfR concentration is not influenced by the acute phase response that occurs in inflammatory processes and, therefore, its measurement is more accurate than serum ferritin when studying iron stores in obese patients. 21 In this study, the increase of ferritin levels detected in both the obese women with METs and the obese women with diabetes was not accompanied by any changes in the other parameters of iron status, including sTfR. These findings argue against the presence of iron overload in these patients and point to inflammation as the main contributor to the elevated ferritin levels. In fact, inflammatory cytokines such as tumor necrosis factor and interleukin-6 have been detected in significant amounts in patients with either insulin-resistance syndrome or diabetes. 22, 23 Regarding clinical practice, our results suggest that ferritin cannot be considered a good index of iron stores in obese women with METs or diabetes. Obesity has recently been associated with iron deficiency in overweight children and adolescents, as well as in obese adults. 24, 25 In this regard, we have reported a moderate degree of iron deficiency among adult non-diabetic obese women. 26 Our results support the idea that iron stores are not significantly increased in obese patients regardless of the presence of METs. Therefore, iron overload may not be a contributor to the development of METs in obese patients. No differences in serum ferritin concentrations were observed in obese patients with METs regarding hypertension, HDL cholesterol and triglycerides. In addition, diabetes, but not other features of METs, was independently related to ferritin in multiple regression analyses. Therefore, our results suggest that the increase of serum ferritin reported in obesity could be related to the high prevalence of diabetes observed in these patients rather than to obesity itself. It should be noted that serum ferritin levels in diabetic patients were unrelated with HbA1c, thus suggesting that the presence of diabetes rather than the degree of diabetes control is the main factor accounting for the high ferritin levels detected in obese patients.
Conclusions
This study provides evidence that obese women with METs show higher ferritin concentrations than obese women Restricted to diabetic patients without current treatment with sulfonylureas or insulin (n ¼ 47). Hyperferritinemia in obesity A Lecube et al without METs. The increase of ferritin is not associated with a decrease in sTfR and, in consequence, iron overload does not appear to exist. This finding suggest that serum ferritin cannot be considered a reliable index of iron stores in these patients. In addition, the increase in ferritin levels detected in obese patients with METs is closely related to the presence of diabetes. Therefore, diabetes should be taken into account when evaluating serum ferritin levels in obese patients. Further studies exploring proinflammatory mediators are necessary to investigate the nature and significance of the relationship between serum ferritin, insulin resistance and obesity.
